PTC Therapeutics Files 8-K on Financial Condition & Reg FD Disclosure

Ticker: PTCT · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1070081

Complexity: simple

Sentiment: neutral

Topics: financial-condition, regulation-fd, corporate-disclosure

TL;DR

**PTC Therapeutics just dropped an 8-K about financials and Reg FD, expect new info soon.**

AI Summary

PTC Therapeutics, Inc. filed an 8-K on January 8, 2024, to report on its 'Results of Operations and Financial Condition' and 'Regulation FD Disclosure'. This filing indicates that the company is providing an update on its financial performance and other material non-public information, likely in preparation for an upcoming earnings call or investor presentation. For investors, this matters because it signals that new financial information is being disclosed, which could impact the stock's valuation and future outlook.

Why It Matters

This filing signals that PTC Therapeutics is disclosing new financial information, which could provide critical insights into its recent performance and future prospects, directly influencing investor sentiment and stock price.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure of financial condition and Regulation FD, indicating transparency rather than an immediate risk.

Analyst Insight

A smart investor would look for the actual content of the 'Results of Operations and Financial Condition' and 'Regulation FD Disclosure' that this 8-K refers to, as this filing is merely a notification of their release, not the full details themselves. This information will likely be found in an accompanying exhibit or a separate press release.

Key Players & Entities

FAQ

What specific items are being reported in this 8-K filing by PTC Therapeutics, Inc.?

PTC Therapeutics, Inc. is reporting on 'Results of Operations and Financial Condition' and 'Regulation FD Disclosure' as per the ITEM INFORMATION sections of the filing dated January 8, 2024.

What is the purpose of a 'Regulation FD Disclosure' as mentioned in the filing?

Regulation FD Disclosure, or Fair Disclosure, is intended to prevent selective disclosure of material non-public information by companies to certain individuals or groups, ensuring that all investors receive important information simultaneously. This filing indicates PTC Therapeutics is making such a disclosure.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on January 8, 2024, which is also the date of the report.

What is the business address and phone number of PTC Therapeutics, Inc. as stated in the filing?

The business address of PTC Therapeutics, Inc. is 100 Corporate Court, South Plainfield, NJ 07080, and their telephone number is (908) 222-7000.

Under which section of the Securities Exchange Act of 1934 is this report filed?

This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Filing Stats: 1,252 words · 5 min read · ~4 pages · Grade level 13.1 · Accepted 2024-01-08 09:27:30

Key Financial Figures

Filing Documents

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition . On January 8, 2024, PTC Therapeutics, Inc. (the "Company") issued a press release (the "press release") announcing certain preliminary (unaudited) financial information for its fiscal year ending December 31, 2023, including that the Company expects to report (i) total unaudited net revenue of approximately $946 million, (ii) total unaudited net product revenue of approximately $661 million, (iii) unaudited net product revenue for Translarna (ataluren) of approximately $355 million and unaudited net product revenue for Emflaza (deflazacort) of approximately $255 million and (iv) collaboration and royalty revenue associated with Evrysdi of approximately $278 million. Final results are subject to completion of the Company's year-end audit.

01. Regulation FD Disclsoure

Item 7.01. Regulation FD Disclsoure. On January 8, 2024, the Company also announced financial guidance for its fiscal year ending December 31, 2024 in the press release, including that the Company anticipates (i) full year total revenues to be between $600 million and $850 million, (ii) GAAP R&D and SG&A expense for the full year 2024 to be between $740 million and $835 million with non-GAAP R&D and SG&A expense for the full year 2024 to be between $660 million and $755 million, including R&D expense milestone payments of up to $65 million and excluding estimated non-cash, stock-based compensation expense of $80 million and (iii) up to $90 million of payments for the full year 2024 upon achievement of potential regulatory success-based milestones from previous acquisition, of which up to $65 million will be recorded as R&D operating expense. The Company announced that on Monday, January 8, 2024 at 10:30 am EST at the 42nd Annual J.P. Morgan Healthcare Conference (the "Conference"), the Company will provide an update on 2023 accomplishments and highlight upcoming 2024 potential value-creating milestones. The Company will also present its preliminary 2023 unaudited financial results and 2024 financial guidance. The presentation will be webcast live on the Events and Presentations page under the Investors section of the Company's website. Following the completion of the Conference, the Company will enter an investor quiet period until it provides its next corporate update. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference into this Item 7.01. This Current Report on Form 8-K and Exhibits 99.1 and 99.2 include a forward-looking financial measure that was not prepared in accordance with accounting principles generally accepted in the United States (GAAP), non-GAAP R&D and SG&A expenses (which excludes non-cash stock-based compensation expense). Management uses this measure when assessing and ide

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated January 8, 2024 issued by PTC Therapeutics, Inc. 99.2 Corporate Presentation – 42nd Annual J.P. Morgan Healthcare Conference 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. PTC Therapeutics, Inc. Date: January 8, 2024 By: /s/ Pierre Gravier Name: Pierre Gravier Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing